Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2017 07:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Appoints Pascale Witz and James Shannon, M.D. to Board of Directors

DUBLIN, Ireland, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
July 25, 2017 08:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Launches CGD Connections™ to Deliver Support and Resources Created by and for the Chronic Granulomatous Disease (CGD) Community

DUBLIN, Ireland, July 25, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
July 14, 2017 08:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces Four Poster Presentations on PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Capsules at Cystinosis Research Network 2017 Family Conference

DUBLIN, Ireland, July 14, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
July 10, 2017 10:49 ET | Source: Horizon Pharma plc

Horizon Pharma plc to Host Second-Quarter 2017 Conference Call and Webcast on Aug. 7, 2017

DUBLIN, Ireland, July 10, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
June 27, 2017 07:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces District Court Decision to Uphold VIMOVO® (naproxen/esomeprazole magnesium) Patents

DUBLIN, Ireland, June 27, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
June 23, 2017 11:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin nebuliser solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S.p.A.

DUBLIN, Ireland, June 23, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) (Horizon), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring...
June 20, 2017 15:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Partners with Global Genes® to Unite the Rare Disease Community at the Biotechnology Innovation Organization (BIO) International Convention

DUBLIN, Ireland, June 20, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
June 19, 2017 08:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine Delayed-Release Capsules) for the Treatment of Nephropathic Cystinosis

DUBLIN, Ireland, June 19, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
June 14, 2017 09:05 ET | Source: Horizon Pharma plc

Horizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled Gout

DUBLIN, Ireland, June 14, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
June 14, 2017 09:00 ET | Source: Horizon Pharma plc

Epidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993

MADRID, Spain, June 14, 2017 (GLOBE NEWSWIRE) -- Results from a new study to be presented tomorrow at the Annual European Congress of Rheumatology (EULAR) 2017 show a 410 percent increase in...